| Autor: |
Helder Cardoso, Ana Margarida Alves, Margarida Marques, Ana Maria Vale, Pedro Pereira, Guilherme Macedo |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
GE: Portuguese Journal of Gastroenterology, Vol 23, Iss 5, Pp 243-248 (2016) |
| Druh dokumentu: |
article |
| ISSN: |
2341-4545 |
| DOI: |
10.1016/j.jpge.2016.04.006 |
| Popis: |
Introduction: Sorafenib chemotherapy is the first-line therapy for patients with hepatocellular carcinoma (HCC) in an advanced stage. The aim of this study was to evaluate prognostic factors of survival in HCC patients treated with sorafenib, in real-life clinical practice. Material and methods: Retrospective study of HCC patients who initiated treatment with sorafenib, following assessment and indication from the multidisciplinary group. Results: There were included 36 patients, mostly male (89%) and with a mean age of 65 years. The main etiologies were chronic hepatitis C (44%) and alcoholic liver disease (36%). Twenty patients (56%) were classified as Child–Pugh A and 16 patients (44%) as Child–Pugh B. Half of the patients group were staged as BCLC C and the remaining as BCLC B. Significant adverse events were observed in 15 patients (42%) and were associated with longer survival (21.5 vs. 3.2 months, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
